Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast
05 August 2024 - 10:05PM
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:
YMAB), a commercial-stage biopharmaceutical company focused on the
development and commercialization of novel radioimmunotherapy and
antibody-based therapeutic products for the treatment of cancer,
today announced it will report second quarter 2024 financial and
operating results before market open on Monday, August 12, 2024.
The Company will hold a conference call and webcast to discuss
these results at 8:00 a.m. ET.
Conference call and webcast
details:
Investors
(domestic): |
(877)
407-0792 |
Investors (international): |
(201) 689-8263 |
To access a live webcast of the update, please
use this link.
About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical
company focused on the development and commercialization of novel,
radioimmunotherapy and antibody-based therapeutic cancer products.
The Company’s technologies include its investigational
Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy
Platform (“PRIT”) and bispecific antibodies generated using the
Y-BiClone platform. The Company’s broad and advanced product
pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk),
the first FDA-approved treatment for patients with relapsed or
refractory high-risk neuroblastoma in the bone or bone marrow after
a partial response, minor response, or stable disease to prior
therapy.
Forward-Looking
StatementsStatements in this press release about future
expectations, plans and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such statements include, but are not limited
to, statements about our business model, including financial
outlook for 2024 and beyond, including estimated operating
expenses, cash burn and DANYELZA product revenue and sufficiency of
cash resources and related assumptions; implied and express
statements regarding the future of the Company’s business,
including with respect to expansion and its goals; the Company’s
plans and strategies, development, commercialization and product
distribution plans; expectations with respect to the Company’s
products and product candidates, including potential territory and
label expansion of DANYELZA and the potential market opportunity
related thereto and potential benefits thereof, and the potential
of the SADA PRIT Technology and potential benefits and applications
thereof; the Company’s mission of delivering better and safer
therapies to patients; expectations relating to key anticipated
development milestones, including potential expansion and
advancement of commercialization and development efforts, including
potential indications, applications and geographies, and the timing
thereof; expectations with respect to current and future clinical
and pre-clinical studies and the Company’s research and development
programs, including with respect to timing and results;
expectations related to the timing of the initiation and completion
of regulatory submissions; additional product candidates and
technologies; expectations regarding collaborations or strategic
partnerships and the potential benefits thereof; expectations
related to the use of cash and cash equivalents, and the need for,
timing and amount of any future financing transaction; expectations
with respect to the Company’s future financial performance; and
other statements that are not historical facts. Words such as
‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’
‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’
‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’
‘‘should,’’ ‘‘target,’’ “will,” ‘‘would’,’ “guidance,” “goal,”
“objective,” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Our product candidates
and related technologies are novel approaches to cancer treatment
that present significant challenges. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various factors, including but not limited to: risks
associated with the Company’s financial condition and need for
additional capital; the risks that actual results of the Company’s
restructuring plan and revised business plan will not be as
expected; risks associated with the Company’s development work;
cost and success of the Company’s product development activities
and clinical trials; the risks of delay in the timing of the
Company’s regulatory submissions or failure to receive approval of
its drug candidates; the risks related to commercializing any
approved pharmaceutical product including the rate and degree of
market acceptance of product candidates; development of sales and
marketing capabilities and risks associated with failure to obtain
sufficient reimbursement for products; the risks related to the
Company’s dependence on third parties including for conduct of
clinical testing and product manufacture; the Company’s ability to
enter into partnerships; the risks related to government
regulation; risks related to market approval, risks associated with
protection of the Company’s intellectual property rights; risks
related to employee matters and managing growth; risks related to
the Company’s common stock, risks associated with macroeconomic
conditions, including the conflict between Russia and Ukraine and
sanctions related thereto, the state of war between Israel and
Hamas and the related risk of a larger regional conflict,
inflation, increased interest rates, uncertain global credit and
capital markets and disruptions in banking systems; and other risks
and uncertainties affecting the Company including those described
in the "Risk Factors" section included in the Company’s Quarterly
Report on Form 10-Q for the quarter ended March 31, 2024, in the
Company’s Quarterly Report on Form 10-Q for the quarter ended June
30, 2024, and future filings and reports by the Company. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and the Company undertakes no
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
DANYELZA® and Y-mAbs® are registered trademarks
of Y-mAbs Therapeutics, Inc.
Investor Contact:Courtney DuganVP, Head of
Investor Relationscdu@ymabs.com
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
Von Jul 2024 bis Aug 2024
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
Von Aug 2023 bis Aug 2024